Last year, while browsing on Aim for a target company to reverse-merge his business into, Dubliner Gerry Brandon spotted something interesting. The potential target company was called Integumen. It was a disaster of a business, with the distinction of being the worst-performing Aim flotation in 2017. By mid-2018 it was as good as dead, with a market cap of £1.2 million. Integumen listed as a loose collection of skincare products and lab science. The idea was that some of the skin products were ready for the market, others were still at R&D stage, and that somehow the thing would hang…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .